ReviewCNS drugs2021
The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update.
Review in CNS drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- Gray matter alteration in medication overuse headache: a coordinates-based activation likelihood estimation meta-analysis.Brain imaging and behavior · 2022Pooled it
- Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study.The journal of headache and pain · 2022Trial
- Diagnosis challenges and accessibility barriers to migraine management in Southeast Asia: results from the South-East Asia Local breAch on MigraiNe Treatment (SEALANT) study.The journal of headache and pain · 2026Article
- Triple network disruption in medication overuse headache: functional signatures and clinical impact.The journal of headache and pain · 2025Article
- Validation of a Self-Screening Questionnaire for Medication Overuse Headache (SSQ-MOH) in a Thai University-based Hospital Headache Clinic.The journal of headache and pain · 2025Article
- Systemic Inflammation and Oxidative Stress Markers in Patients With Medication Overuse Headache.Brain and behavior · 2025Article
- Offset analgesia as a marker of dysfunctional pain modulation in episodic and chronic migraine.The journal of headache and pain · 2025Article
- Drug-induced headache reports: a comprehensive disproportionality and time-to-onset pharmacovigilance study using the FAERS database (2018-2024).Frontiers in pain research (Lausanne, Switzerland) · 2025Article
- Filling the data gap on CGRP mAb therapy in low- to middle-income countries in Southeast Asia: insights from a real-world study in Thailand.The journal of headache and pain · 2024Article
- Article
- Association between Body Mass Index and Medication-Overuse Headache among Individuals with Migraine: A Cross-Sectional Study.Obesity facts · 2024Article
- Article
- Managing Migraine: Medication Overuse Headache and Treatment with Eptinezumab.Pain and therapy · 2023Article
- Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real-world clinical evidence in a severely impaired patient population.Brain and behavior · 2023Article
- Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study.Frontiers in neurology · 2023Article
- Assessing and managing medication overuse headache in Australian clinical practice.BMJ neurology open · 2023Article
- New Oral Drugs for Migraine.CNS drugs · 2022Review
- Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.Cephalalgia : an international journal of headache · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medication overuse headache (MOH), the development or worsening of chronic headache resulting from frequent and excessive intake of medications used for acute treatment of headache, is a common secondary headache disorder and is associated with significant personal and societal burdens. The plausible physiologic mechanism is that chronic exposure to acute care migraine treatment leads to suppression of endogenous antinociceptive systems, consequently facilitating the trigeminal nociceptive process via up-regulation of the calcitonin gene-related peptide (CGRP) system. Recognizing and preventing its development is an integral aspect of migraine management, as medication overuse is a modifiable risk factor in the progression from episodic to chronic migraine. Over the years, MOH has been difficult to treat and has generated much controversy. Ongoing debates exist over the diagnostic criteria and treatment strategies, particularly regarding the roles of formal detoxification and preventive treatment. The arrival of the anti-CGRP monoclonal antibodies has also challenged our views of MOH and its treatment. This review outlines the evolution of MOH diagnostic criteria, presents the current understanding of MOH pathogenesis and discusses the debates over its development and treatment. Data on the efficacy of anti-CGRP monoclonal antibodies in the setting of medication overuse is also presented. These results indicate that patients with medication overuse, who are treated with these new medications, may not need to be detoxified in order to treat MOH. In light of these developments, it is likely that in the future MOH will be more readily diagnosed and treatment will result in better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.